RS 바이러스 백신 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)

Respiratory Syncytial Virus Vaccine Market - Scope of Report

TMR's report on the global respiratory syncytial virus vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global respiratory syncytial virus vaccine market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global respiratory syncytial virus vaccine market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the respiratory syncytial virus vaccine market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global respiratory syncytial virus vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global respiratory syncytial virus vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global respiratory syncytial virus vaccine market.

The report delves into the competitive landscape of the global respiratory syncytial virus vaccine market. Key players operating in the global respiratory syncytial virus vaccine market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global respiratory syncytial virus vaccine market profiled in this report.

Key Questions Answered in global respiratory syncytial virus vaccine Market Report:

• What is the sales/revenue generated by respiratory syncytial virus vaccine across all regions during the forecast period?
• What are the opportunities in the global respiratory syncytial virus vaccine market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Respiratory Syncytial Virus Vaccine Market - Research Objectives and Research Approach

The comprehensive report on the global respiratory syncytial virus vaccine market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global respiratory syncytial virus vaccine market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global respiratory syncytial virus vaccine market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Respiratory Syncytial Virus Vaccine Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, 2020-2035
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Healthcare Expenditure Data Across Key Countries
• 5.2. Technological Advancements
• 5.3. Regulatory Scenario across Key Regions / Countries
• 5.4. PORTER's Five Forces Analysis
• 5.5. PESTEL Analysis
• 5.6. Key Industry Events

6. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Vaccine Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Vaccine Type, 2020-2035
  • 6.3.1. Recombinant/Subunit Vaccines
  • 6.3.2. mAB Injection
  • 6.3.3. mRVaccines
  • 6.3.4. Others
• 6.4. Market Attractiveness By Vaccine Type

7. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Age Group

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Age Group, 2020-2035
  • 7.3.1. Adults & Geriatrics
  • 7.3.2. Children & Pregnant Mothers
• 7.4. Market Attractiveness By Age Group

8. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Sales Channel

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Sales Channel, 2020-2035
  • 8.3.1. Retail Pharmacies
  • 8.3.2. Hospital Pharmacies
  • 8.3.3. Others
• 8.4. Market Attractiveness By Sales Channel

9. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Region

10. North America Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Vaccine Type, 2020-2035
  • 10.2.1. Recombinant/Subunit Vaccines
  • 10.2.2. mAB Injection
  • 10.2.3. mRVaccines
  • 10.2.4. Others
• 10.3. Market Value Forecast By Age Group, 2020-2035
  • 10.3.1. Adults & Geriatrics
  • 10.3.2. Children & Pregnant Mothers
• 10.4. Market Value Forecast By Sales Channel, 2020-2035
  • 10.4.1. Retail Pharmacies
  • 10.4.2. Hospital Pharmacies
  • 10.4.3. Others
• 10.5. Market Value Forecast By Country, 2020-2035
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Vaccine Type
  • 10.6.2. By Age Group
  • 10.6.3. By Sales Channel
  • 10.6.4. By Country

11. Europe Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Vaccine Type, 2020-2035
  • 11.2.1. Recombinant/Subunit Vaccines
  • 11.2.2. mAB Injection
  • 11.2.3. mRVaccines
  • 11.2.4. Others
• 11.3. Market Value Forecast By Age Group, 2020-2035
  • 11.3.1. Adults & Geriatrics
  • 11.3.2. Children & Pregnant Mothers
• 11.4. Market Value Forecast By Sales Channel, 2020-2035
  • 11.4.1. Retail Pharmacies
  • 11.4.2. Hospital Pharmacies
  • 11.4.3. Others
• 11.5. Market Value Forecast By Country / Sub-region, 2020-2035
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Spain
  • 11.5.5. Italy
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Vaccine Type
  • 11.6.2. By Age Group
  • 11.6.3. By Sales Channel
  • 11.6.4. By Country / Sub-region

12. Asia Pacific Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Vaccine Type, 2020-2035
  • 12.2.1. Recombinant/Subunit Vaccines
  • 12.2.2. mAB Injection
  • 12.2.3. mRVaccines
  • 12.2.4. Others
• 12.3. Market Value Forecast By Age Group, 2020-2035
  • 12.3.1. Adults & Geriatrics
  • 12.3.2. Children & Pregnant Mothers
• 12.4. Market Value Forecast By Sales Channel, 2020-2035
  • 12.4.1. Retail Pharmacies
  • 12.4.2. Hospital Pharmacies
  • 12.4.3. Others
• 12.5. Market Value Forecast By Country / Sub-region, 2020-2035
  • 12.5.1. China
  • 12.5.2. Japan
  • 12.5.3. India
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Vaccine Type
  • 12.6.2. By Age Group
  • 12.6.3. By Sales Channel
  • 12.6.4. By Country / Sub-region

13. Latin America Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Vaccine Type, 2020-2035
  • 13.2.1. Recombinant/Subunit Vaccines
  • 13.2.2. mAB Injection
  • 13.2.3. mRVaccines
  • 13.2.4. Others
• 13.3. Market Value Forecast By Age Group, 2020-2035
  • 13.3.1. Adults & Geriatrics
  • 13.3.2. Children & Pregnant Mothers
• 13.4. Market Value Forecast By Sales Channel, 2020-2035
  • 13.4.1. Retail Pharmacies
  • 13.4.2. Hospital Pharmacies
  • 13.4.3. Others
• 13.5. Market Value Forecast By Country / Sub-region, 2020-2035
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Vaccine Type
  • 13.6.2. By Age Group
  • 13.6.3. By Sales Channel
  • 13.6.4. By Country / Sub-region

14. Middle East & Africa Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Vaccine Type, 2020-2035
  • 14.2.1. Recombinant/Subunit Vaccines
  • 14.2.2. mAB Injection
  • 14.2.3. mRVaccines
  • 14.2.4. Others
• 14.3. Market Value Forecast By Age Group, 2020-2035
  • 14.3.1. Adults & Geriatrics
  • 14.3.2. Children & Pregnant Mothers
• 14.4. Market Value Forecast By Sales Channel, 2020-2035
  • 14.4.1. Retail Pharmacies
  • 14.4.2. Hospital Pharmacies
  • 14.4.3. Others
• 14.5. Market Value Forecast By Country / Sub-region, 2020-2035
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Vaccine Type
  • 14.6.2. By Age Group
  • 14.6.3. By Sales Channel
  • 14.6.4. By Country / Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2024)
• 15.3. Company Profiles
  • 15.3.1. GSK plc
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Product Portfolio
    • 15.3.1.4. Business Strategies
    • 15.3.1.5. Recent Developments
  • 15.3.2. Moderna, Inc.
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Product Portfolio
    • 15.3.2.4. Business Strategies
    • 15.3.2.5. Recent Developments
  • 15.3.3. Pfizer, Inc.
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Product Portfolio
    • 15.3.3.4. Business Strategies
    • 15.3.3.5. Recent Developments
  • 15.3.4. Sanofi
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Product Portfolio
    • 15.3.4.4. Business Strategies
    • 15.3.4.5. Recent Developments
  • 15.3.5. AstraZeneca
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Product Portfolio
    • 15.3.5.4. Business Strategies
    • 15.3.5.5. Recent Developments
  • 15.3.6. MAXVAX Biotechnology Limited
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Product Portfolio
    • 15.3.6.4. Business Strategies
    • 15.3.6.5. Recent Developments
  • 15.3.7. Guangzhou Patronus Biotech Co., Ltd.
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Product Portfolio
    • 15.3.7.4. Business Strategies
    • 15.3.7.5. Recent Developments
  • 15.3.8. Sinocelltech Ltd.
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Product Portfolio
    • 15.3.8.4. Business Strategies
    • 15.3.8.5. Recent Developments
  • 15.3.9. Shenzhen Shenxin Biotechnology Co., Ltd
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Product Portfolio
    • 15.3.9.4. Business Strategies
    • 15.3.9.5. Recent Developments
  • 15.3.10. Starna Therapeutics
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Product Portfolio
    • 15.3.10.4. Business Strategies
    • 15.3.10.5. Recent Developments
  • 15.3.11. Blue Lake Biotechnology Inc.
    • 15.3.11.1. Company Overview
    • 15.3.11.2. Financial Overview
    • 15.3.11.3. Product Portfolio
    • 15.3.11.4. Business Strategies
    • 15.3.11.5. Recent Developments